NASDAQ:NRXP NRx Pharmaceuticals (NRXP) Stock Price, News & Analysis $3.75 -0.36 (-8.76%) Closing price 07/24/2026 04:00 PM EasternExtended Trading$3.80 +0.06 (+1.47%) As of 07/24/2026 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About NRx Pharmaceuticals Stock (NASDAQ:NRXP) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get NRx Pharmaceuticals alerts:Sign Up Key Stats Today's Range$3.75▼$4.1850-Day Range$2.97▼$4.6252-Week Range$1.62▼$5.05Volume783,309 shsAverage Volume742,403 shsMarket Capitalization$135.86 millionP/E RatioN/ADividend YieldN/APrice Target$38.25Consensus RatingModerate Buy Company Overview NRx Pharmaceuticals, Inc. is a clinical-stage specialty biopharmaceutical company focused on the development and repurposing of small-molecule therapeutics for central nervous system and rare disease indications. The company’s research strategy centers on advancing compounds with established safety profiles into new neurological and inflammatory conditions, leveraging translational science and biomarker-driven trial design to accelerate clinical development. NRx’s pipeline includes Ifenprodil, an NMDA receptor antagonist in investigation for acute respiratory distress syndrome and inflammatory muscle disorders, as well as investigational formulations targeting depressive and cognitive disorders. Since securing global rights to its lead assets, NRx has initiated multiple proof-of-concept studies in the United States and Europe, collaborating with academic institutions and clinical research organizations to evaluate safety and efficacy across a range of indications. The company’s development programs are designed to address high-unmet-need patient populations, applying precision-medicine principles to optimize dosing regimens and patient selection. By building on decades of prior clinical experience with these molecules, NRx aims to reduce development timelines and costs relative to novel drug discovery. Headquartered in New York, NRx Pharmaceuticals operates a lean corporate structure, with R&D activities supported by a network of external partners and contract research organizations. The company is led by a management team with deep expertise in pharmaceutical development, regulatory affairs and commercial strategy, drawing on experience at major biotech and global healthcare companies. Through strategic collaborations and disciplined capital allocation, NRx seeks to advance its product candidates efficiently toward regulatory milestones and, ultimately, market approval.AI Generated. May Contain Errors. Read More NRx Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks54th Percentile Overall ScoreNRXP MarketRank™: NRx Pharmaceuticals scored higher than 54% of companies evaluated by MarketBeat, and ranked 458th out of 834 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.1 / 5Analyst RatingModerate Buy Consensus RatingNRx Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on no strong buy ratings, 4 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialNRx Pharmaceuticals has a consensus price target of $38.25, representing about 920.0% upside from its current price of $3.75.Amount of Analyst CoverageNRx Pharmaceuticals has only been the subject of 4 research reports in the past 90 days.Read more about NRx Pharmaceuticals' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for NRx Pharmaceuticals are expected to grow in the coming year, from ($0.30) to $0.59 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of NRx Pharmaceuticals is -3.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of NRx Pharmaceuticals is -3.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about NRx Pharmaceuticals' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted18.28% of the float of NRx Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverNRx Pharmaceuticals has a short interest ratio ("days to cover") of 7.4.Change versus previous monthShort interest in NRx Pharmaceuticals has recently increased by 14.87%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldNRx Pharmaceuticals does not currently pay a dividend.Dividend GrowthNRx Pharmaceuticals does not have a long track record of dividend growth. News and Social Media3.8 / 5News Sentiment1.08 News SentimentNRx Pharmaceuticals has a news sentiment score of 1.08. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.92 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for NRx Pharmaceuticals this week, compared to 5 articles on an average week.Search Interest14 people have searched for NRXP on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.MarketBeat Follows11 people have added NRx Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 450% compared to the previous 30 days. Company Ownership0.3 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, NRx Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders6.40% of the stock of NRx Pharmaceuticals is held by insiders.Percentage Held by Institutions4.27% of the stock of NRx Pharmaceuticals is held by institutions.Read more about NRx Pharmaceuticals' insider trading history. Receive NRXP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for NRx Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. NRXP Stock News HeadlinesNRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Receives Consensus Rating of "Moderate Buy" from BrokeragesJuly 21, 2026 | americanbankingnews.comIs NRx Pharmaceuticals, Inc. (NRXP) Stock Positioned for Growth Through Depression and PTSD Treatment Innovation?July 15, 2026 | insidermonkey.comHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - but now he believes he's found something better. This under-the-radar company sits at the intersection of America's two most important industries, including AI, pays massive dividends, and attracted a famous money manager who put 60% of his multi-billion-dollar fund into it. Tilson is revealing the name and ticker symbol completely free - no credit card or email required.July 26 at 1:00 AM | Stansberry Research (Ad)NRx Pharmaceuticals Responds to Recent Public Statements Regarding Kadima DisputeJune 25, 2026 | globenewswire.comNRx Pharmaceuticals (Nasdaq: NRXP) Subsidiary HOPE Therapeutics Treats First Patients Using Zeta Surgical's FDA-Cleared Zeta TMS Navigation SystemJune 25, 2026 | globenewswire.comKadima Neuropsychiatry Institute Files Suit Against NRx Pharmaceuticals (NASDAQ: NRXP), Alleging Breach of Contract and Misrepresentation in Connection with AcquisitionJune 24, 2026 | businesswire.comZETA SURGICAL® Announces Successful Treatment of First Patient with Zeta TMS Navigation System at HOPE TherapeuticsJune 23, 2026 | prnewswire.comNRx Pharmaceuticals Announces FDA Grant of Expanded Access Protocol for Use of D-Cycloserine-based NRX-101 for Augmentation of Transcranial Magnetic Stimulation in the ...June 22, 2026 | markets.businessinsider.comSee More Headlines NRXP Stock Analysis - Frequently Asked Questions How have NRXP shares performed this year? NRx Pharmaceuticals' stock was trading at $2.71 at the beginning of the year. Since then, NRXP shares have increased by 38.4% and is now trading at $3.75. How were NRx Pharmaceuticals' earnings last quarter? NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) announced its earnings results on Friday, May, 15th. The company reported ($0.04) earnings per share for the quarter, beating the consensus estimate of ($0.05) by $0.01. The firm earned $1.07 million during the quarter, compared to analyst estimates of $19.43 million. Read the conference call transcript. When did NRx Pharmaceuticals' stock split? NRx Pharmaceuticals shares reverse split on Tuesday, April 2nd 2024.The 1-10 reverse split was announced on Tuesday, April 2nd 2024. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, April 2nd 2024. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. How do I buy shares of NRx Pharmaceuticals? Shares of NRXP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of NRx Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that NRx Pharmaceuticals investors own include NVIDIA (NVDA), Broadcom (AVGO), Arista Networks (ANET), Adobe (ADBE), Meta Platforms (META), GE Aerospace (GE) and Disc Medicine (IRON). Company Calendar Last Earnings5/15/2026Today7/26/2026Next Earnings (Estimated)8/17/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (2m+) 1-Year History Jul 25 Oct 25 Jan 26 Apr 26 Jul 26 NRXP's financial health is in the Green zone, according to TradeSmith. NRXP has been in this zone for over 2 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - DRUGS Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:NRXP CIK1719406 Webwww.bigrockpartners.com Phone(484) 254-6134FaxN/AEmployees2Year Founded2015Price Target and Rating Average Price Target for NRx Pharmaceuticals$38.25 High Price Target$49.00 Low Price Target$25.00 Potential Upside/Downside+920.0%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage6 Analysts Profitability EPS (Trailing Twelve Months)($1.09) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$28.62 million Net MarginsN/A Pretax Margin-1,070.47% Return on EquityN/A Return on Assets-202.92% Debt Debt-to-Equity RatioN/A Current Ratio0.29 Quick Ratio0.29 Sales & Book Value Annual Sales$1.23 million Price / Sales110.46 Cash FlowN/A Price / Cash FlowN/A Book Value($0.54) per share Price / Book-6.94Miscellaneous Outstanding Shares36,230,000Free Float33,910,000Market Cap$135.86 million OptionableOptionable Beta2.19 Social Links The 10 Best High-Yield Dividend Stocks for 2026Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free Report This page (NASDAQ:NRXP) was last updated on 7/26/2026 by MarketBeat.com Staff. From Our PartnersUniversal basic income is not impossible. It exist (kind of)Robert Kiyosaki, author of Rich Dad Poor Dad, is highlighting an income strategy he calls the Patriot Income P...Freedom Financial | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredBofA: Digital Dollar Coming 2025-2030Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the...Decentralized Masters | SponsoredBlackRock's $2.8B Clue (most investors missed)BlackRock's new fund on the emerging financial grid hit 2.8 billion in assets in just three months, according ...Awesomely | SponsoredOxford Club Analyst’s Urgent AI WarningAlexander Green, Chief Investment Strategist at The Oxford Club, is sharing a private presentation with a warn...The Oxford Club | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...Porter & Company | SponsoredAugust 6 could be a BIG day for one AI companyOne AI company's revenue has surged 757 percent in the past year, earning it an A rating from Louis Navellier'...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NRx Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share NRx Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free NRXP Stock Alerts